Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Novartis

Status and phase: Completed; Phase 4

Conditions: Diastolic Dysfunction, Symptomatic Heart Failure

Treatments: Drug: valsartan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00171106

CVAL489B2401

Details and patient eligibility

About

This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Symptomatic diastolic heart failure
• Breathlessness with physical exertion

Exclusion criteria

• Uncontrolled hypertension
• Asthma, COPD, or abnormal lung function
• History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
• Liver, kidney, or pancreas disease
• Allergy to valsartan

Other protocol-defined exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind